Mixed connective tissue disease

Author: Dr Susannah Fraser, MBChB, FRCP (Edin), Consultant Dermatologist, NHS Fife, Scotland, United Kingdom; Chief Editor: A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand, February 2016.


What is mixed connective tissue disease?

Mixed connective tissue disease is a rare connective tissue disorder, with an autoimmune basis. The condition has features of 3 more common connective tissue diseases, hence its name.

The symptoms tend to occur in sequence over a number of years, so diagnosis can be difficult.

Mixed connective tissue disease is also known as Sharp syndrome.

What causes mixed connective tissue disease?

The cause of mixed connective tissue disease is not fully known. Due to the presence of autoantibodies, it is classified is an autoimmune disease.

It is more common in patients with HLA-DR4, suggesting it has a genetic background.

Who gets mixed connective tissue disease?

  • Mixed connective tissue disease is approximately 4 times more common in women than in men
  • It often affects women under 30 years of age.
  • Children may be affected.

What are the clinical features of mixed connective tissue disease?

The course of mixed connective tissue disease may be similar to systemic lupus erythematosus, or systemic sclerosis.

  • Early symptoms often involve the hands, with Raynaud phenomenon and sausage-shaped swelling of the digits.
  • Malaise, myositis and arthritis may also develop

Mixed connective tissue disease can be particularly severe in children, due to:

  • Cardiac disease
  • Renal impairment
  • Thrombocytopenia

Dermatological manifestations of mixed connective tissue disease include:

Mixed connective tissue disease

Complications of mixed connective tissue disease

Later stage complications of mixed connective tissue disease include nephritis, pericarditis and myocarditis, and interstitial lung disease.

What investigations should be undertaken in patients with suspected mixed connective tissue disease?

The presence of high titres of auto-antibodies against the U1-ribonucleoprotein (RNP) complex is a defining feature of mixed connective tissue disease. This was previously termed an antibody to ‘extractable nuclear antigens’ (anti-ENA). The U1 small nuclear ribonucleoprotein particle is a target of autoreactive B cells and T cells.

Other tests

  • Blood count may reveal anaemia, thrombocythaemia, and leukopenia.
  • Renal function may be impaired.
  • Muscle enzymes may be elevated.
  • C-reactive protein and erythrocyte sedimentation rate (ESR) may be elevated.
  • Patients may also have hypergammaglobulinaemia.
  • Urinalysis may show proteinuria and haematuria.
  • Chest Xray may show pleural thickening and fibrosis and signs of pulmonary hypertension.
  • Echocardiogram may reveal pericarditis and pulmonary hypertension.
  • Abnormal oesophageal motility may also be detected on imaging.

What treatment options are available for mixed connective tissue disease?

General

Prescribed treatment

Treatment may depend on the relative severity of lupus-like, systemic sclerosis-like and polymyositis-like aspects of mixed connective tissue disease.

What is the outlook for mixed connective tissue disease?

  • Around one-third of patients with mixed connective tissue have mild disease, requiring only anti-inflammatories, and may go into remission where no U1-RNP antibodies are detected.
  • Another third of patients have a progressive course developing progressive systemic sclerosis, which has a poor outcome.
  • Pulmonary hypertension is the main cause of death

 

Related Information